-
平臺編號：bio-68394
-
國際編號：CRL-2369?
-
細胞信息： C1R-neo
-
規(guī)格：frozen
-
用途：ATCC原裝細胞
-
服務費用：
加載中…… - 訂購
-
注意事項：僅用于科學研究或者工業(yè)應用等非醫(yī)療目的不可用于人類或動物的臨床診斷或治療，非藥用，非食用（產(chǎn)品信息以出庫為準）
C1R-neo
生長狀態(tài)：懸浮生長
細胞類型：B淋巴細胞
是否是腫瘤細胞：0
物種來源：人
數(shù)量：大量
ATCC Number：CRL-2369?
運輸方式：凍存運輸
器官來源：外周血
細胞形態(tài)：淋巴樣
規(guī)格：0.2ml Designations: C1R-neo
Depositors: ?F Grumet
Biosafety Level:2 [Cells contain herpesvirus ]
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension
Organism: Homo sapiens
Morphology:lymphoblast
Source: Organ: peripheral blood
Cell Type: B lymphoblast; Epstein-Barr virus (EBV) transformed
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
DNA Profile (STR):Amelogenin: X
CSF1PO: 6,10
D13S317: 11,13
D16S539: 9,13
D5S818: 10,13
D7S820: 7,12
THO1: 8
TPOX: 8
vWA: 17
Comments:C1R-neo is a stable transfectant cell line established in 1987 by transfection by electroporation of the C1R cell line with a modified neomycin drug-resistant eukaryotic vector, pSP65-Neo. The vector did not carry an insert. [38581 ]
C1R-neo does not secrete or express HLA B7.
C1R is a human B-cell lymphoblastoid line lacking surface HLA A and B antigens. C1R was derived from Hmy.2 B-LCL by gamma irradiation followed by selection for Class I monoclonal antibodies and complement. [23312 ]
C1R-neo may be used as a control for C1R-sB7 (CRL-2370), in CTL experiments and for producing control supernatants.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Iscove's Modified Dulbecco's Medium, Catalog No. 30-2005. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Subculturing: Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)
Cultures can be maintained by addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension in fresh medium at 5 X 10(5) viable cells/ml.
Maintain cultures at cell concentrations between 5 X 10(5) and 2 X 10(6) viable cells/ml.
Preservation: culture medium 95%; DMSO, 5%
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2005
recommended serum:ATCC 30-2020
parental cell line:ATCC CRL-1993
derived from same cell line:ATCC CRL-2370
derived from same cell line:ATCC CRL-2371
References: 23312: Storkus WJ, et al. Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes. Proc. Natl. Acad. Sci. USA 86: 2361-2364, 1989. PubMed: 2784569
38581: Grumet FC, et al. Soluble form of an HLA-B7 class I antigen specifically suppresses humoral alloimmunization. Hum. Immunol. 40: 228-234, 1994. PubMed: 7960967
38582: Hiraki DD, et al. Bioengineered soluble HLA-B7. Genesis, characterization, and occurrence of dimerization. Hum. Immunol. 40: 235-246, 1994. PubMed: 7960968
細胞類型：B淋巴細胞
是否是腫瘤細胞：0
物種來源：人
數(shù)量：大量
ATCC Number：CRL-2369?
運輸方式：凍存運輸
器官來源：外周血
細胞形態(tài)：淋巴樣
規(guī)格：0.2ml Designations: C1R-neo
Depositors: ?F Grumet
Biosafety Level:2 [Cells contain herpesvirus ]
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension
Organism: Homo sapiens
Morphology:lymphoblast
Source: Organ: peripheral blood
Cell Type: B lymphoblast; Epstein-Barr virus (EBV) transformed
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
DNA Profile (STR):Amelogenin: X
CSF1PO: 6,10
D13S317: 11,13
D16S539: 9,13
D5S818: 10,13
D7S820: 7,12
THO1: 8
TPOX: 8
vWA: 17
Comments:C1R-neo is a stable transfectant cell line established in 1987 by transfection by electroporation of the C1R cell line with a modified neomycin drug-resistant eukaryotic vector, pSP65-Neo. The vector did not carry an insert. [38581 ]
C1R-neo does not secrete or express HLA B7.
C1R is a human B-cell lymphoblastoid line lacking surface HLA A and B antigens. C1R was derived from Hmy.2 B-LCL by gamma irradiation followed by selection for Class I monoclonal antibodies and complement. [23312 ]
C1R-neo may be used as a control for C1R-sB7 (CRL-2370), in CTL experiments and for producing control supernatants.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Iscove's Modified Dulbecco's Medium, Catalog No. 30-2005. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Subculturing: Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)
Cultures can be maintained by addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension in fresh medium at 5 X 10(5) viable cells/ml.
Maintain cultures at cell concentrations between 5 X 10(5) and 2 X 10(6) viable cells/ml.
Preservation: culture medium 95%; DMSO, 5%
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2005
recommended serum:ATCC 30-2020
parental cell line:ATCC CRL-1993
derived from same cell line:ATCC CRL-2370
derived from same cell line:ATCC CRL-2371
References: 23312: Storkus WJ, et al. Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes. Proc. Natl. Acad. Sci. USA 86: 2361-2364, 1989. PubMed: 2784569
38581: Grumet FC, et al. Soluble form of an HLA-B7 class I antigen specifically suppresses humoral alloimmunization. Hum. Immunol. 40: 228-234, 1994. PubMed: 7960967
38582: Hiraki DD, et al. Bioengineered soluble HLA-B7. Genesis, characterization, and occurrence of dimerization. Hum. Immunol. 40: 235-246, 1994. PubMed: 7960968
